Berinert denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for berinert are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Limits Quantity for Berinert — and Why You Can Appeal

Berinert (C1 esterase inhibitor) is used to treat acute attacks of hereditary angioedema (HAE). BCBS quantity-limit denials on Berinert typically reflect the plan's attempt to align dispensing to what it considers a statistically average attack frequency or a fixed number of vials per period. Because HAE attack rates vary dramatically between patients — and because under-treatment of a severe attack can be life-threatening — these limits are among the most successfully appealed in the rare-disease space.

## Why This Denial Is Appealable

HAE attack frequency is not uniform. Patients with frequent, severe, or unpredictable attacks have a documented clinical need that can exceed a plan's default quantity ceiling. If your prescriber has charted your personal attack history, attack severity, and prior inadequate response to a lower supply, you have the foundation for a medically necessary exception. BCBS is required under its own coverage policy to consider individual clinical circumstances, not just population averages.

## Federal Appeal Framework

• Internal appeal: Submit within the timeframe on your denial notice (typically 180 days). BCBS must respond within 30 days for non-urgent requests or 72 hours for urgent/concurrent care.
• External review (ACA §2719): If the internal appeal is denied, you have the right to an independent external review. The external reviewer is not employed by BCBS and must apply current clinical standards.
• ERISA §503 (employer-sponsored plans): You are entitled to a full-and-fair review with access to the clinical criteria used.
• Expedited track: If your condition poses an imminent risk, request expedited external review — decisions are issued within 72 hours.
• Window: Most states allow external review requests within four months of a final internal denial.

## Documentation to Gather

1. Attack log: Dated records of every HAE attack in the past 12–24 months, including severity, treatment required, and any emergency or hospital visits. 2. Prescriber letter: A detailed medical-necessity letter from your immunologist or HAE specialist explaining why the requested quantity is the minimum needed given your documented attack pattern. 3. FDA prescribing label: Obtain the current label and confirm the approved indications and dosing guidance; your prescriber's letter should reference that your use is within label. 4. BCBS coverage policy: Request the exact published policy number and criteria used to set the quantity limit; your appeal must address each criterion explicitly. 5. Prior-treatment history: Documentation of any prior acute treatments, their outcomes, and any inadequate or delayed responses.

## Criteria-Mapping Structure

Create a table with two columns: (1) each requirement stated in the BCBS quantity-limit policy, and (2) the exact chart fact that satisfies it. For example: if the policy requires documentation of attack frequency, cite the dated attack log. If it requires specialist involvement, attach the treating specialist's credentials and notes. Address every criterion — unanswered criteria are the most common reason appeals fail at the first review level.